The cost of health insurance for a family jumps to $27,000

Prescription drugs and chronic diseases are contributing to the higher price.

October 22, 2025 Check out STAT+

Sponsored By

Adobe STAT+ | Companies tout a novel payment model for obesity drugs, other medications in drive to lower costs Startups are offering employers a way to lower insurance costs by not covering pricey medications, but subsidizing drugs like Wegovy when paid in cash. By Elaine Chen STAT+ | The cost of health insurance for a family jumps to $27,000 KFF survey finds premiums grew 6% in 2025, compared to general inflation of 2.7% and wage growth of 4%. Health insurance for a family is now $27,000 a year. By Tara Bannow STAT+ | Moderna says key study of its CMV vaccine, expected to be its next big win, failed The results are significant setback for a company already facing pressure from Wall Street and the federal government. By Jason Mast and Matthew Herper Opinion: Would you contract dysentery for $7,300? On the "First Opinion Podcast," Jill Fisher and Jake Eberts discuss their work on compensation for healthy medical research volunteers. By Torie Bosch STAT+ | CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies Gilead says it is still in "active" discussions with payers and expects 75% access for Yeztugo by December By Ed Silverman STAT+ | European oncology experts roll out guidance for use of large language models in clinical care  ESMO guidance designed to address opportunities and risks in patient-facing applications, AI tools for clinicians, standardized electronic health records. By Katherine MacPhail and Brittany Trang Adobe Opinion: The U.S. experiment with profit-driven health care has failed The U.S. experiment with profit-driven health care has failed. It's time to change everything By Steffie Woolhandler, David U. Himmelstein, Adam W. Gaffney, and Danny McCormick Opinion: Corporate support cannot make up for threats to the NIH budget Many are turning to private industry to fund research whose NIH support is at risk. But privatization of medical research has its own problems. By Jerry Avorn

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser